Jude Children’s Research Hospital, COG, the Eastern Cooperative Oncology Group (ECOG), the Alliance for Clinical Trials in Oncology (Cancer and Leukemia Group B), and MD Anderson Cancer Center, both children and young adults with Ph-like ALL and co-existing IKZF1 deletions demonstrated an inferior 5-year EFS of 48% in children and 19% in young adults, compared to 72% in children and 43% for young adults with Ph-like ALL without IKZF1 deletion [4]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.